120 related articles for article (PubMed ID: 32598307)
1. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.
Ahmadimanesh M; Naeini MB; Rouini MR; Shadnia S; Ghazi-Khansari M
Drug Metab Pers Ther; 2020 Jun; ():. PubMed ID: 32598307
[TBL] [Abstract][Full Text] [Related]
2. Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.
Ahmadimanesh M; Naeini MB; Rouini MR; Shadnia S; Ghazi-Khansari M
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681776
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and
Jeong HC; Bae SH; Bae JW; Lee S; Kim A; Jang Y; Shin KH
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31744222
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.
Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L
Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
Halling J; Weihe P; Brosen K
Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
[TBL] [Abstract][Full Text] [Related]
9. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
Pedersen RS; Damkier P; Brosen K
Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
[TBL] [Abstract][Full Text] [Related]
10. Gender Dependency in Streoselective Pharmacokinetics of Tramadol and Its Phase I Metabolites in Relation to CYP2D6 Phenotype in Iranian Population.
Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Iran J Pharm Res; 2018; 17(2):767-782. PubMed ID: 29881433
[TBL] [Abstract][Full Text] [Related]
11. Sequencing CYP2D6 for the detection of poor-metabolizers in post-mortem blood samples with tramadol.
Fonseca S; Amorim A; Costa HA; Franco J; Porto MJ; Santos JC; Dias M
Forensic Sci Int; 2016 Aug; 265():153-9. PubMed ID: 26926096
[TBL] [Abstract][Full Text] [Related]
12. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
Paar WD; Poche S; Gerloff J; Dengler HJ
Eur J Clin Pharmacol; 1997; 53(3-4):235-9. PubMed ID: 9476037
[TBL] [Abstract][Full Text] [Related]
13. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition.
Long T; Cristofoletti R; Cicali B; Michaud V; Dow P; Turgeon J; Schmidt S
J Clin Pharmacol; 2022 Jan; 62(1):76-86. PubMed ID: 34383318
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis of tramadol and
Lee J; Yoo HD; Bae JW; Lee S; Shin KH
Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
[No Abstract] [Full Text] [Related]
16. Tramadol-Related Deaths: Genetic Analysis in Relation to Metabolic Ratios.
Aly SM; Tartar O; Sabaouni N; Hennart B; Gaulier JM; Allorge D
J Anal Toxicol; 2022 Aug; 46(7):791-796. PubMed ID: 34480795
[TBL] [Abstract][Full Text] [Related]
17. Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study.
Bianconi G; Malissin I; Labat L; Khoudour N; Houzé P; Pallet N; Mégarbane B; Declèves X
Clin Toxicol (Phila); 2022 Mar; 60(3):382-385. PubMed ID: 34287102
[TBL] [Abstract][Full Text] [Related]
18. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.
Pedersen RS; Damkier P; Brøsen K
Eur J Clin Pharmacol; 2006 Jul; 62(7):513-21. PubMed ID: 16763825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
